title: GNAQ and BRAF mutations show differential activation of the mTOR pathway in human transformed cells.
abstract: Somatic mutations in GNAQ gene were described as being the main oncogenic activation in uveal melanomas, whereas mutations in BRAF gene have been described as a key genetic alteration that contributes to skin melanoma development. We have previously reported differential activation of the MAPK and AKT/mTOR signalling pathways in uveal and skin melanomas harbouring, respectively, GNAQ and BRAF mutations. The aim of this work was to compare the functional effect of GNAQ and BRAF mutations in mTOR and MAPK pathway activation, cell proliferation and apoptosis. In this work, we performed transient transfection of HEK293 cells with BRAF(WT), BRAF(V 600E), GNAQ(WT), GNAQ(Q209P) and GNAQ(Q209L) vectors. We treated melanoma cell lines displaying different BRAF and GNAQ mutational status with the mTOR inhibitor RAD001 and with the MEK1/2 inhibitor U0126 and evaluated the effects in the growth of the cell lines and in mTOR and MAPK pathway effectors expression. At variance with the significant increase in the level of pmTOR Ser2448 and pS6 Ser235/236 proteins observed in cells transfected with BRAF vectors, no significant alteration in mTOR pathway effectors was observed in cells transfected with the three GNAQ expressing vectors. Also, GNAQ overexpression enhances Stat3 activation, which might mediate GNAQ oncogenic effects. None of the vectors led to significant differences in proliferation or apoptosis in the transfected cell lines. Cell lines harbouring a BRAF mutation were more sensitive to RAD001 treatment. U0126 leads to the reduction of MAPK and mTOR pathways activation in all cell lines tested. Our results indicate that GNAQ and BRAF activation drive distinct intracellular signalling pathways that may be useful for therapeutic decisions in human melanomas.
authors.affiliation: Institute of Molecular Pathology and Immunology, University of Porto , Porto , Portugal.
authors.forename: Helena
authors.initials: H
authors.lastname: Pópulo
authors.forename: Sandra
authors.initials: S
authors.lastname: Tavares
authors.forename: Alexandra
authors.initials: A
authors.lastname: Faustino
authors.forename: Joana B
authors.initials: JB
authors.lastname: Nunes
authors.forename: José Manuel
authors.initials: JM
authors.lastname: Lopes
authors.forename: Paula
authors.initials: P
authors.lastname: Soares
keywords: BRAF; GNAQ; MAPK; Melanoma; mTOR
references.citation: Melanoma Res. 2010 Apr;20(2):107-17
references.pmid: 20173664
references.citation: Br J Cancer. 2006 Aug 21;95(4):496-505
references.pmid: 16880792
references.citation: Nature. 2005 Aug 4;436(7051):720-4
references.pmid: 16079850
references.citation: PLoS One. 2012;7(7):e40439
references.pmid: 22808163
references.citation: Dermatol Ther. 2006 Jan-Feb;19(1):19-25
references.pmid: 16405566
references.citation: Nature. 2009 Jan 29;457(7229):599-602
references.pmid: 19078957
references.citation: Methods Enzymol. 1995;255:395-412
references.pmid: 8524126
references.citation: APMIS. 2007 Oct;115(10):1161-76
references.pmid: 18042149
references.citation: J Natl Cancer Inst. 1990 Jul 4;82(13):1107-12
references.pmid: 2359136
references.citation: Am J Surg. 1980 Oct;140(4):522-6
references.pmid: 7425236
references.citation: Transl Oncol. 2010 Apr;3(2):65-79
references.pmid: 20360931
references.citation: PLoS Med. 2008 Jan 22;5(1):e8
references.pmid: 18215105
references.citation: J Transl Med. 2005 Oct 28;3:39
references.pmid: 16255777
references.citation: J Invest Dermatol. 2008 Aug;128(8):2013-23
references.pmid: 18323781
references.citation: Clin Cancer Res. 2012 Aug 15;18(16):4345-55
references.pmid: 22733540
references.citation: J Invest Dermatol. 2004 Oct;123(4):xvi-xvii
references.pmid: 15373800
references.citation: Br J Cancer. 2006 Oct 23;95(8):955-60
references.pmid: 16953237
references.citation: Cancer Res. 2010 Nov 1;70(21):8736-47
references.pmid: 20959481
references.citation: Clin Exp Ophthalmol. 2004 Dec;32(6):639-47
references.pmid: 15575836
references.citation: Invest Ophthalmol Vis Sci. 1991 Dec;32(13):3198-208
references.pmid: 1748551
references.citation: Int J Cancer. 2004 Apr 10;109(3):377-84
references.pmid: 14961576
references.citation: N Engl J Med. 2006 Jul 6;355(1):51-65
references.pmid: 16822996
references.citation: Clin Exp Metastasis. 1997 Sep;15(5):509-18
references.pmid: 9247253
references.citation: J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2005;23(2):105-61
references.pmid: 16291526
references.citation: J Invest Dermatol. 2008 Aug;128(8):2003-12
references.pmid: 18323787
references.citation: Cancer Res. 2006 Feb 1;66(3):1500-8
references.pmid: 16452206
references.citation: Cancer. 1998 Oct 15;83(8):1664-78
references.pmid: 9781962
references.citation: Oncogene. 2011 Jun 9;30(23):2691-6
references.pmid: 21317923
references.citation: Int J Cancer. 1995 Jul 17;62(2):155-61
references.pmid: 7622289
references.citation: Nature. 2007 Feb 22;445(7130):851-7
references.pmid: 17314971
references.citation: Curr Opin Oncol. 2007 Mar;19(2):116-20
references.pmid: 17272983
references.citation: Pigment Cell Melanoma Res. 2011 Feb;24(1):254-7
references.pmid: 21029395
references.citation: J Clin Endocrinol Metab. 2012 Jul;97(7):E1139-49
references.pmid: 22549934
references.citation: Int J Cancer. 1996 May 3;66(3):380-7
references.pmid: 8621261
references.citation: Br J Ophthalmol. 2011 May;95(5):715-9
references.pmid: 20805136